- Asterias Biotherapeutics (NYSEMKT:AST) is up 10% on double normal volume in response to its announcement that, based on the recommendation from the Data Monitoring Committee, its Phase 1/2a clinical trial, SCiStar, assessing AST-OPC1 in acute spinal injury will continue as planned without modification.
- According to ClinicalTrials.gov, the estimated study completion date is September 2018. The enrollment target is 35 subjects.
Asterias Bio's study of AST-OPC1 in acute spinal cord injury to continue; shares ahead 10%
Recommended For You
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
AST | - | - |
Asterias Biotherapeutics, Inc. |